• Biomolecules & Therapeutics
• /
• v.9 no.1
• /
• pp.55-62
• /
• 2001

CJC-50100 is a recombinant hepatitis B virus surface antigen (HBsAg) expressed in yeast. The general pharmacological properties of CJC-50100 were evaluated in mice, rats, dogs and isolated guinea pig ileum. The doses were 0.33~33.3 $\mu$g/kg i.m. for mice and rats and 3.3~9.9 $\mu$g/kg i.v. for dogs. The concentrations of 0.002~0.02 $\mu$g/ml were used for the assay with guinea pig ileum. Intramuscular administration of CJC-50100 at the doses did not alter general behavior and the responses for central nervous system, smooth muscle, gastrointestinal system, cardiovascular and respiratory system, and water and electrolytes excretion. In summary, CJC-50100 had no pharmacological effect in these studies even up to the 100-fold of the expected clinical dose, 20 $\mu$g/man/60 kg.